Plasma N-terminal pro-brain natriuretic peptide and adrenomedullin: prognostic utility and prediction of benefit from carvedilol in chronic ischemic left ventricular dysfunction. Australia-New Zealand Heart Failure Group.
about
Science review: natriuretic peptides in critical illnessThe role of natriuretic peptides for the diagnosis of left ventricular dysfunctionRecent developments in non-invasive cardiologyPrimary care-based multifaceted, interdisciplinary medical educational intervention for patients with systolic heart failure: lessons learned from a cluster randomised controlled trialSerum 25-hydroxyvitamin D is not related to cardiac natriuretic peptide in nulliparous and lactating women.Natriuretic Peptide testing in primary careNatriuretic peptides (BNP and NT-proBNP): measurement and relevance in heart failureHow well does B-type natriuretic peptide predict death and cardiac events in patients with heart failure: systematic reviewDepressive symptoms affect the relationship of N-terminal pro B-type natriuretic peptide to cardiac event-free survival in patients with heart failureTriiodothyronine and brain natriuretic peptide: similar long-term prognostic values for chronic heart failure.Evaluation of multiple biomarkers of cardiovascular stress for risk prediction and guiding medical therapy in patients with stable coronary disease.Natriuretic peptides in the diagnosis and management of heart failureRelation of baseline plasma MMP-1 levels to long-term all-cause mortality in patients with known or suspected coronary artery disease referred for coronary angiography.N-terminal pro B type natriuretic peptide, but not the new putative cardiac hormone relaxin, predicts prognosis in patients with chronic heart failure.Diagnostic and prognostic evaluation of left ventricular systolic heart failure by plasma N-terminal pro-brain natriuretic peptide concentrations in a large sample of the general populationN-terminal brain natriuretic peptide and subsequent hospital admission for worsening heart failure.NT-proBNP in heart failure: therapy decisions and monitoring.Correlation of N-terminal fragment of B-type natriuretic peptide levels with clinical, laboratory, and echocardiographic abnormalities in children with sickle cell disease.Plasma N-terminal pro-B-type natriuretic peptide as long-term prognostic marker after major vascular surgery.B-type natriuretic peptide measurement in heart failure.Brain natriuretic peptide in the contemporary management of congestive heart failure.N-terminal proBNP: a novel biomarker for the diagnosis, risk stratification and management of congestive heart failure.Impact of Exhaled Breath Acetone in the Prognosis of Patients with Heart Failure with Reduced Ejection Fraction (HFrEF). One Year of Clinical Follow-upPlasma N-terminal pro-B-type natriuretic peptide is predictive of perioperative cardiac events in patients undergoing vascular surgeryThe prognostic value of N-terminal proB-type natriuretic peptide.The prognostic value of anemia, right-heart catheterization and neurohormones in chronic heart failure.Clinical use and pathogenetic basis of laboratory tests for the evaluation of primary arterial hypertension.Role of B-type natriuretic peptide (BNP) and NT-proBNP in clinical routineCanadian Cardiovascular Society Consensus Conference recommendations on heart failure update 2007: Prevention, management during intercurrent illness or acute decompensation, and use of biomarkers.B-type natriuretic peptide: a critical review.The ability of heart failure specialists to accurately predict NT-proBNP levels based on clinical assessment and a previous NT-proBNP measurement.Serial monitoring of brain natriuretic peptide concentrations for drug therapy management in patients with chronic heart failure.B-type natriuretic peptides: prognostic markers in stable coronary artery disease.The Importance of Amino-terminal pro-Brain Natriuretic Peptide Testing in Clinical Cardiology.Prognostic utility of B-type natriuretic peptides in patients with heart failure and renal dysfunction.B-type natriuretic peptides in heart failure.Natriuretic peptides in heart failure: where we are, where we are going.The paradox of low BNP levels in obesity.Novel biomarkers in chronic heart failure.Mid-regional pro-adrenomedullin in acute heart failure: a better biomarker or just another biomarker?
P2860
Q24799740-C89ED281-57EA-4349-8ACF-3A02EE5511E7Q26825665-C5C43ACF-FECE-442A-8179-AB0F92B1B4EBQ30458413-0CC370B4-54AE-42DE-B7F7-70956B4B7AEFQ30489956-0105C3B0-CCC4-433A-9B99-D1BD2D522EDDQ33403893-509EFA11-E5BD-4364-BDE5-79C1C42FAE07Q33572286-BCFC8944-7862-405B-9346-F5A8E75246E7Q33902623-6D75DB84-CCFF-4C3F-8249-8DBF6F4CD2A0Q33932889-ED0B4B4C-D8D9-4C49-8C71-A8B46A6FCA94Q33980903-5E16754C-B460-4C2F-B5E2-69193A945E31Q34190826-0E715D9A-F7AD-4C24-BBA7-F1824F9A7C56Q34241396-5963DE09-C741-4FC5-BE88-0558F3A5F79CQ35015563-E5DBCDB4-E898-47E8-8A2C-352A8349C9B2Q35091397-46C4B18F-CF9E-415C-B171-4F387FA7DAF3Q35581367-49D67800-1487-4EF8-A051-D8609B6B9542Q35582125-CE06936B-FA55-4DB1-B0AD-6E3F3B6E4810Q35583858-7F07BA7C-09EE-4CE5-B0FF-2D509E6A46D2Q35677310-F98EF88A-7C9D-4C10-80EA-36AD578CB4CAQ35742699-8B5DA0D1-EB3D-4499-B1F8-0656D2D5CF14Q35773192-E6BAED0E-15AE-4BCB-A6BB-2F95CA98AF64Q35911696-3FA73FCD-719E-4187-B340-69B68F5EBD26Q36050481-A375184C-1B6B-477A-A82D-D801A462D044Q36124913-CC3CA298-D233-426E-9A3B-F383C949BD30Q36234809-0031FDDF-D698-4DB2-8340-AC09B5EFFC0EQ36237962-89207A0F-4557-440D-BE6C-821F56995437Q36304293-898F17D3-D252-4FC4-835E-002F16B6D37DQ36352015-9328F7F2-5B67-4E0A-8CD3-CBAC5FB0BA83Q36359500-7D0F1706-A2BA-44B1-A563-AEAC0E6F6690Q36477929-E3B7B222-0EA9-42ED-B161-7E547DC695FAQ36716456-24E98820-C8C6-4112-A846-FC81E4C8A63DQ36724549-0C1515E5-4340-4330-80CA-11A0F97AD710Q36944131-0C10DD0E-502E-48DA-ADD8-645C528CB026Q37092258-F44F7057-4F85-41D9-9365-0F14FB86ECE7Q37118998-0051750C-212B-4ADA-8D57-ABD88DB792BFQ37277937-43ACD693-DA8A-41DF-9A53-066D4920894AQ37463142-08B6D13F-AC9D-47D4-B266-F81333905059Q37755096-D3B35F89-45C1-47C4-A5EA-BA1156D5C098Q37790310-4A8079F0-10D0-43B2-ACE0-EBEAAC64D830Q37869374-95317F76-A6F5-4417-BE99-F3CDA1C22F9AQ37997237-24B88144-48B9-4AB7-868E-A58FC3C06CD4Q38021707-7399A107-4988-4A63-BB19-6B2A719A3B51
P2860
Plasma N-terminal pro-brain natriuretic peptide and adrenomedullin: prognostic utility and prediction of benefit from carvedilol in chronic ischemic left ventricular dysfunction. Australia-New Zealand Heart Failure Group.
description
2001 nî lūn-bûn
@nan
2001年の論文
@ja
2001年学术文章
@wuu
2001年学术文章
@zh
2001年学术文章
@zh-cn
2001年学术文章
@zh-hans
2001年学术文章
@zh-my
2001年学术文章
@zh-sg
2001年學術文章
@yue
2001年學術文章
@zh-hant
name
Plasma N-terminal pro-brain na ...... w Zealand Heart Failure Group.
@en
Plasma N-terminal pro-brain na ...... w Zealand Heart Failure Group.
@nl
type
label
Plasma N-terminal pro-brain na ...... w Zealand Heart Failure Group.
@en
Plasma N-terminal pro-brain na ...... w Zealand Heart Failure Group.
@nl
prefLabel
Plasma N-terminal pro-brain na ...... w Zealand Heart Failure Group.
@en
Plasma N-terminal pro-brain na ...... w Zealand Heart Failure Group.
@nl
P2093
P921
P1476
Plasma N-terminal pro-brain na ...... w Zealand Heart Failure Group.
@en
P2093
A M Richards
Australia-New Zealand Heart Failure Group
C Frampton
E A Espiner
M G Nicholls
S MacMahon
T G Yandle
P304
P356
10.1016/S0735-1097(01)01269-4
P407
P577
2001-06-01T00:00:00Z